Incretin & Metabolic Receptor Agonists
Semaglutide
Also known as Ozempic · Wegovy · Rybelsus
Last reviewed: 2026-11-19
Evidence status & limitations
Large randomized trials support product-specific indications; results depend on the population, endpoints and approved formulation.
Regulatory status
FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.
Ozempic · Type 2 Diabetes
Glycemic control in adults with type 2 diabetes, with diet and physical activity.
Authoritative label recordWegovy · Weight Management
Long-term weight reduction in adults with obesity, or overweight with a weight-related condition; the indicated product also covers patients 12 and older with obesity.
Authoritative label recordWegovy · Cardiovascular Risk
Major cardiovascular event risk reduction in adults with established cardiovascular disease and overweight or obesity.
Authoritative label recordWegovy injection · Liver Disease
Treatment of noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3) in adults; accelerated approval based on a surrogate endpoint, with confirmation of clinical benefit required.
Authoritative label record
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Gastrointestinal symptoms, pancreatitis and gallbladder events are concerns; FDA labeling includes a rodent thyroid C-cell tumor boxed warning.
Key sources
Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.
Related compounds
- Retatrutide
Same scientific class · A 39-amino-acid chain. · Late-stage human trials
- Tirzepatide
Same scientific class · A 39-amino-acid chain. · FDA-approved for specific indications